Browse > Article
http://dx.doi.org/10.4333/KPS.2007.37.6.369

Phenotype Based on Pharmacokinetic/Pharmacodynamic Parameters and Genotype Correlations of Immunosupressants  

Lee, Yong-Bok (College of Pharmacy and Institute of Bioequivalence and Bridging Study, Chonnam National University)
Cho, Hea-Young (Pharmacological Research Department, NITR, KFDA)
Publication Information
Journal of Pharmaceutical Investigation / v.37, no.6, 2007 , pp. 369-376 More about this Journal
Abstract
Cyclosporine (CsA) and tacrolimus (FK506) have a narrow therapeutic range, and their pharmacokinetic (PK) characteristic varies among individual. They are also substrates for cytochrome P450 (CYP) 3A4, 3A5 genes, and P-glycoprotein, the product of the multidrug resistance 1 (MDR1). The aims were to investigate the relationship between CYP3A and MDR1 genotypes and their PK parameters among healthy subjects. We investigated the genotype for CYP3A and MDR1 gene in human using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. After oral administration of CsA and FK506 (100 mg and 1 mg, respectively), whole blood samples were taken up to 24 hours. Blood CsA and FK506 concentrations were measured by LC/MS/MS. Each PK parameters were compared using Kruskal-Wallis test according to the CYP3A and MDR1 genotype. We found that the values of AVC for CsA were significantly different among CYP3A5 and MDR1 exon 26 (C3435T) genotypes (P=0.037 and P=0.049). On the other hand, the AUC for FK506 was significantly different only among CYP3A5 genotypes (P=0.013). The results clearly demonstrate the effects of CYP3A5 and MDR1 exon 26 on Cys and FK506 disposition.
Keywords
Cyclosporine; Tacrolimus; CYP3A; MDR1; Genotype; Pharmacokinetics;
Citations & Related Records
연도 인용수 순위
  • Reference
1 S. Matsuda, F. Shibasaki, K. Takehana, H. Mori, E. Nishida and S. Koyasu, Two distinct action mechanisms of immunophilin-ligand complexes for the blockade of T-cell activation, EMBO rep., 1, 428-434 (2000)   DOI   ScienceOn
2 P. Pintavorn and B.J. Ballermann, TGF-beta and the endothelium during immune injury, Kidney Int., 51, 1401-1412 (1997)   DOI   ScienceOn
3 M.G. Crespo-Leiro, Tacrolimus in heart transplantation. Transpl. Proc., 35, 1981-1983 (2003)
4 P. Belitsky, G.A. Levy and A. Johnston, Neoral absorption profiling: and evolution in effectiveness, Transpl. Proc., 32(Suppl 3A), 45S-52S (2000)
5 W. Sadee, Pharmacogenomics: the implementation phase, AAPS PharmSci., 4(2), E5 (2002)
6 R. Lama, F. Santos, F.J. Algar, A. Alvarez and C. Baamonde, Lung transplants with tacrolimus and mycophenolate mofetil, Transpl. Proc., 35, 1968-1973 (2003)
7 M.F. Herbert, Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery, Adv. Drug Dliv. Rev., 27, 201-214 (1997)   DOI   ScienceOn
8 V.W. Armstron and M. Oellerich, New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus and azatioprine, Clin. Biochem., 34, 9-16 (2001)   DOI   ScienceOn
9 M. Ingelman-Sundberg, M. Oscarson and R.A. McLellan, Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment, Trends Pharmacal. Sci., 20, 342-349 (1999)   DOI   ScienceOn
10 W.E. Evans and M.V. Relling, Pharmacogenomics: translating functioncal genomics into rational therapeutics, Science, 286(5439), 487 (1999)   DOI   ScienceOn
11 A. Volosov. K.I. Napoli and S.J. Soldin, Simultaneous simple and fast quantification of three major immunosuppressants by liquid chromatography- tandem massspectrometry, Clin. Biochem., 34(4), 285-290 (2001)   DOI   ScienceOn
12 U. Ceglarek, J. Lembcke, G.M. Fiedler, M. Werner, H. Witzigmann, J.P. Hauss and J. Thiery, Rapid simultaneous quantification of immunosuppressants in transplant patients by turbulent flow chromatography combined with tandem mass spectrometry, Clin. Chim. Acta., 346(2), 181-190 (2004)   DOI   ScienceOn